Dr. Ramesh Rengan, MD, PhD

Dr. Rengan practices at Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center.

Dr. Rengan's NPI, 1801981428, was assigned on October 3, 2006. Dr. Rengan graduated from University Of Michigan Medical School in 2001. Dr. Rengan's Washington license number on file is MD60337539.

Dr. Rengan's primary practice is Fred Hutchinson Cancer Center, at 825 Eastlake Avenue East, Seattle, WA 98109.

Dr. Rengan's primary practice is Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center. The medical group on file is UW Physicians. Dmand AI also links Dr. Rengan to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rengan practices, 2 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Rengan's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Rengan is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Rengan's licenses on file in 5 states: Washington, Pennsylvania, California, New York and New Jersey.

Dmand AI lists bone cancer radiation and lung cancer radiation among the conditions Dr. Rengan treats.

CMS data shows 64 Medicare services from Dr. Rengan across 1 procedure code in 2024, for 72 Medicare patients. Medicare paid $1,170 for them. Every service was in an office.

CMS counts 72 Medicare patients who saw Dr. Rengan in 2024. The largest group is 65 to 74, with 49 patients. 75% of them have cancer, and 60% have high blood pressure. Their average risk score is 1.28, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Rengan's median patient age at 73, with 56% women.

In 2019, Dr. Rengan wrote 29 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $562 in total drug cost. In 2018, CMS named 22 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Rengan for performance year 2024, reported through an alternative payment model (APM). Dr. Rengan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rengan as offering telehealth.

Dmand AI links 105 papers to Dr. Rengan, published from 2010 to 2024. 2018 was the busiest year, with 8. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Radiotherapy Dosage. Dr. Rengan has published most often in Int J Radiat Oncol Biol Phys. Dr. Rengan's most frequent co-authors are Charles Brian Simone, MD, Charles B. Simone, MD and Smith Apisarnthanarax, MD.

Dmand AI links Dr. Rengan to 7 clinical trials, 4 of them phase 2 studies. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Carcinoma, Renal Cell. Abramson Cancer Center at Penn Medicine sponsors the most, 4.

CMS Open Payments shows 76 general payments to Dr. Rengan from 10 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 46% of the total. Siemens Medical Solutions USA, Inc. paid the most, $16,460.

Dmand AI lists 1 award for Dr. Rengan, most recently CMS Stage 1 EHR in 2012. Dr. Rengan serves on Journal “Advances in Radiation Oncology." and National Cancer Institute’s Radiation and Immune Modulation Working Group.

Dr. Rengan graduated from University Of Michigan Medical School in 2001.

Dr. Rengan is in network with 17 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 9. Check the plan with the practice before a visit.